Viridian Therapeutics, Inc. (VRDN)
18.66
+0.32
(+1.74%)
USD |
NASDAQ |
Oct 09, 16:00
18.69
+0.03
(+0.16%)
After-Hours: 20:00
Viridian Therapeutics Cash from Operations (Quarterly) : -105.32M for June 30, 2026
Cash from Operations (Quarterly) Chart
Historical Cash from Operations (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -105.32M |
| March 31, 2026 | -119.65M |
| December 31, 2025 | -24.23M |
| September 30, 2025 | -84.61M |
| June 30, 2025 | -75.37M |
| March 31, 2025 | -92.65M |
| December 31, 2024 | -73.33M |
| September 30, 2024 | -67.71M |
| June 30, 2024 | -46.06M |
| March 31, 2024 | -45.22M |
| December 31, 2023 | -38.00M |
| September 30, 2023 | -38.98M |
| June 30, 2023 | -45.21M |
| March 31, 2023 | -61.97M |
| December 31, 2022 | |
| September 30, 2022 | |
| June 30, 2022 | -18.09M |
| March 31, 2022 | -21.04M |
| December 31, 2021 | -16.54M |
| September 30, 2021 | -11.88M |
| June 30, 2021 | -14.63M |
| March 31, 2021 | -11.54M |
| December 31, 2020 | -9.436M |
| September 30, 2020 | -5.095M |
| June 30, 2020 | -6.789M |
| Date | Value |
|---|---|
| March 31, 2020 | -8.459M |
| December 31, 2019 | -7.806M |
| September 30, 2019 | -9.267M |
| June 30, 2019 | -7.174M |
| March 31, 2019 | -11.81M |
| December 31, 2018 | -8.175M |
| September 30, 2018 | -6.802M |
| June 30, 2018 | -4.506M |
| March 31, 2018 | -7.361M |
| December 31, 2017 | -7.243M |
| September 30, 2017 | -5.663M |
| June 30, 2017 | -7.078M |
| March 31, 2017 | -8.183M |
| December 31, 2016 | -3.287M |
| September 30, 2016 | -7.238M |
| June 30, 2016 | -2.008M |
| March 31, 2016 | -2.222M |
| December 31, 2015 | -1.299M |
| September 30, 2015 | -2.304M |
| June 30, 2015 | -2.186M |
| March 31, 2015 | -1.109M |
| December 31, 2014 | -0.9968M |
| September 30, 2014 | -0.831M |
| June 30, 2014 | |
| March 31, 2014 |
Cash From Operations Definition
Represents the net cash flow from the company's business operations.
Cash from Operations (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Operations (Quarterly) Benchmarks
| Vertex Pharmaceuticals, Inc. | 1.125B |
| TG Therapeutics, Inc. | 39.26M |
| Travere Therapeutics, Inc. | 58.07M |
| ACADIA Pharmaceuticals, Inc. | 100.78M |
| Alnylam Pharmaceuticals, Inc. | 326.72M |
Cash from Operations (Quarterly) Related Metrics
| Cash from Investing (Quarterly) | -231.16M |
| Cash from Financing (Quarterly) | 325.12M |
| Free Cash Flow | -335.52M |
| Free Cash Flow Per Share (Quarterly) | -0.9884 |
| Free Cash Flow to Equity (Quarterly) | -298.34M |
| Free Cash Flow to Firm (Quarterly) | -98.32M |
| Free Cash Flow Yield | -18.62% |